A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton)
Research payments
$9,354,771
Through program year 2023, $9,354,771 in research payments was reported against A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton), across 1,386 payments, paid by Chiesi USA, Inc..
- Paid by
- Chiesi USA, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $8,726,039 | 1,274 |
| 2022 | Research | $628,732 | 112 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Alexander White Daytona Beach, FL Named on 70 payments
- Lilia Ables Miami, FL Named on 43 payments
- Robert Garver Andalusia, AL Named on 36 payments
- Donald Quinn Bristol, TN Named on 27 payments
- Brian Zeno Columbus, OH Named on 25 payments
- Giralt Yanez Pembroke Pines, FL Named on 23 payments
- Juan Fernandez Miami, FL Named on 22 payments
- Thomas Siler Saint Charles, MO Named on 21 payments
- Jose Cardona Miami, FL Named on 21 payments
- Julian Guerrero Miami, FL Named on 19 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.